Fernando De la Hoz-Restrepo

Summary

Affiliation: Universidad Nacional de Colombia
Country: Colombia

Publications

  1. ncbi request reprint [Evaluating the burden of disease caused by human papillomavirus in Bogota]
    Fernando De la Hoz-Restrepo
    Departamento de Salud Publica, Facultad de Medicina, Universidad Nacional de Colombia, Bogota
    Rev Salud Publica (Bogota) 11:454-67. 2009
  2. ncbi request reprint Potential epidemiological and economical impact of two rotavirus vaccines in Colombia
    Fernando de la Hoz
    Facultad de Medicina, Departamento de Salud Publica, Universidad Nacional de Colombia, Carrera 30 45 03, Edificio 471, Oficina 150, Bogota D C, Colombia
    Vaccine 28:3856-64. 2010
  3. ncbi request reprint Clinical characteristics of patients hospitalized with severe respiratory illness during influenza seasons in the cities of Bogota and Manizales, Colombia 2000-2006
    Karol Cotes
    Departamento de Salud Publica, Facultad de Medicina, Universdad Nacional de Colombia, Bogota, Colombia
    Rev Salud Publica (Bogota) 14:129-42. 2012
  4. doi request reprint Systematic review of incremental non-vaccine cost estimates used in cost-effectiveness analysis on the introduction of rotavirus and pneumococcal vaccines
    Fernando De la Hoz-Restrepo
    Epidemiology and Public Health Evaluation Group, Universidad Nacional de Colombia, Bogota, Colombia
    Vaccine 31:C80-7. 2013
  5. ncbi request reprint Eight years of hepatitis B vaccination in Colombia with a recombinant vaccine: factors influencing hepatitis B virus infection and effectiveness
    Fernando de la Hoz
    Universidad Nacional de Colombia, Ciudad Universitaria, Cra 30 Cll 45, Edificio 471, Facultad de Medicina, Oficina 150, Bogota, Colombia
    Int J Infect Dis 12:183-9. 2008
  6. doi request reprint Cost-effectiveness of pneumococcal conjugate vaccines of 7, 10, and 13 valences in Colombian children
    Carlos Castañeda-Orjuela
    Epidemiology and Public Health Evaluation Group, Department of Public Health, Universidad Nacional de Colombia, Carrera 30 45 03, Office 150, Bogota DC Colombia
    Vaccine 30:1936-43. 2012
  7. doi request reprint How cost effective is universal varicella vaccination in developing countries? A case-study from Colombia
    Angel Paternina-Caicedo
    Research Group in Health Economics GIES, Universidad de Cartagena, Colombia, Piedra de Bolívar, Avd El Consulado, Calle 30 No 48 152, Cartagena de Indias, Colombia
    Vaccine 31:402-9. 2013
  8. doi request reprint Cost-effectiveness of the introduction of the pneumococcal polysaccharide vaccine in elderly Colombian population
    Carlos Castañeda-Orjuela
    Epidemiology and Public Health Evaluation Group, Department of Public Health, Faculty of Medicine, Universidad Nacional de Colombia, Carrera 30 45 03, Office 150, Bogota D C, Colombia
    Vaccine 29:7644-50. 2011
  9. ncbi request reprint [The impact of pneumococcal disease on adults living in Bogota, Colombia, 2008]
    Carlos Castañeda-Orjuela
    Departamento de Salud Publica, Facultad de Medicina, Universidad Nacional de Colombia
    Rev Salud Publica (Bogota) 12:38-50. 2010
  10. doi request reprint Using standardized tools to improve immunization costing data for program planning: the cost of the Colombian Expanded Program on Immunization
    Carlos Castañeda-Orjuela
    Epidemiology and Public Health Evaluation Group, Universidad Nacional de Colombia, Bogota, Colombia
    Vaccine 31:C72-9. 2013

Collaborators

Detail Information

Publications14

  1. ncbi request reprint [Evaluating the burden of disease caused by human papillomavirus in Bogota]
    Fernando De la Hoz-Restrepo
    Departamento de Salud Publica, Facultad de Medicina, Universidad Nacional de Colombia, Bogota
    Rev Salud Publica (Bogota) 11:454-67. 2009
    ..A study was carried out in Bogota aimed at estimating the burden of disease associated with human papillomavirus infection (HPV) and the potentially avoidable percentage due to using new vaccines...
  2. ncbi request reprint Potential epidemiological and economical impact of two rotavirus vaccines in Colombia
    Fernando de la Hoz
    Facultad de Medicina, Departamento de Salud Publica, Universidad Nacional de Colombia, Carrera 30 45 03, Edificio 471, Oficina 150, Bogota D C, Colombia
    Vaccine 28:3856-64. 2010
    ..In conclusion, vaccinating against rotavirus in Colombia with either vaccine would be very cost effective. If cost per vaccinated children falls below USD$3 per dose vaccination would be cost saving...
  3. ncbi request reprint Clinical characteristics of patients hospitalized with severe respiratory illness during influenza seasons in the cities of Bogota and Manizales, Colombia 2000-2006
    Karol Cotes
    Departamento de Salud Publica, Facultad de Medicina, Universdad Nacional de Colombia, Bogota, Colombia
    Rev Salud Publica (Bogota) 14:129-42. 2012
    ....
  4. doi request reprint Systematic review of incremental non-vaccine cost estimates used in cost-effectiveness analysis on the introduction of rotavirus and pneumococcal vaccines
    Fernando De la Hoz-Restrepo
    Epidemiology and Public Health Evaluation Group, Universidad Nacional de Colombia, Bogota, Colombia
    Vaccine 31:C80-7. 2013
    ..To review the approaches used in the cost-effectiveness analysis (CEAs) literature to estimate the cost of expanded program on immunization (EPI) activities, other than vaccine purchase, for rotavirus and pneumococcal vaccines...
  5. ncbi request reprint Eight years of hepatitis B vaccination in Colombia with a recombinant vaccine: factors influencing hepatitis B virus infection and effectiveness
    Fernando de la Hoz
    Universidad Nacional de Colombia, Ciudad Universitaria, Cra 30 Cll 45, Edificio 471, Facultad de Medicina, Oficina 150, Bogota, Colombia
    Int J Infect Dis 12:183-9. 2008
    ..To evaluate the effectiveness of a recombinant hepatitis B vaccine used in endemic areas of Colombia, as well as risk factors associated with hepatitis B virus (HBV) infection and carriage after vaccine introduction...
  6. doi request reprint Cost-effectiveness of pneumococcal conjugate vaccines of 7, 10, and 13 valences in Colombian children
    Carlos Castañeda-Orjuela
    Epidemiology and Public Health Evaluation Group, Department of Public Health, Universidad Nacional de Colombia, Carrera 30 45 03, Office 150, Bogota DC Colombia
    Vaccine 30:1936-43. 2012
    ..We evaluate the cost-effectiveness of the introduction of pneumococcal conjugate vaccines of 7, 10, and 13 valences in the Colombian EPI...
  7. doi request reprint How cost effective is universal varicella vaccination in developing countries? A case-study from Colombia
    Angel Paternina-Caicedo
    Research Group in Health Economics GIES, Universidad de Cartagena, Colombia, Piedra de Bolívar, Avd El Consulado, Calle 30 No 48 152, Cartagena de Indias, Colombia
    Vaccine 31:402-9. 2013
    ..The present study assesses the potential epidemiological and economic impact of one-dose and two-dose varicella vaccination schemes in Colombia, a south American upper middle-income country...
  8. doi request reprint Cost-effectiveness of the introduction of the pneumococcal polysaccharide vaccine in elderly Colombian population
    Carlos Castañeda-Orjuela
    Epidemiology and Public Health Evaluation Group, Department of Public Health, Faculty of Medicine, Universidad Nacional de Colombia, Carrera 30 45 03, Office 150, Bogota D C, Colombia
    Vaccine 29:7644-50. 2011
    ..We developed an evaluation of cost-effectiveness of implementing PPV-23 in Colombian population over 60 years...
  9. ncbi request reprint [The impact of pneumococcal disease on adults living in Bogota, Colombia, 2008]
    Carlos Castañeda-Orjuela
    Departamento de Salud Publica, Facultad de Medicina, Universidad Nacional de Colombia
    Rev Salud Publica (Bogota) 12:38-50. 2010
    ..Estimating the impact of pneumococcal disease amongst adults living in Bogota, Colombia...
  10. doi request reprint Using standardized tools to improve immunization costing data for program planning: the cost of the Colombian Expanded Program on Immunization
    Carlos Castañeda-Orjuela
    Epidemiology and Public Health Evaluation Group, Universidad Nacional de Colombia, Bogota, Colombia
    Vaccine 31:C72-9. 2013
    ..Costs also are needed for cost-effectiveness analysis of introducing new vaccines. We describe a costing tool that improves the speed, accuracy, and availability of EPI costs and that was piloted in Colombia...
  11. ncbi request reprint Effectiveness of the monovalent rotavirus vaccine in Colombia: a case-control study
    Karol Cotes-Cantillo
    Universidad Nacional de Colombia, Bogota, Colombia
    Vaccine 32:3035-40. 2014
    ..To assess the effectiveness of the monovalent rotavirus vaccine (RV1) to prevent rotavirus diarrhea admissions to emergency departments (ED) in Colombia...
  12. pmc How protective is cervical cancer screening against cervical cancer mortality in developing countries? The Colombian case
    Luz Angela Chocontá-Piraquive
    Public Health Department, Universidad Nacional de Colombia, Bogota, Colombia
    BMC Health Serv Res 10:270. 2010
    ..To address this problem an ecological analysis, at department level, was carried out in Colombia to assess the relationship between cervical screening characteristics and cervical cancer mortality rates...
  13. ncbi request reprint [Relationships between psychosocial risk behavior and the family in adolescents' from Suba, an urban area in Bogotá]
    Juan C González-Quiñones
    Facultad de Medicina, Fundación Universitaria Juan N Corpas, Bogota, Colombia
    Rev Salud Publica (Bogota) 13:67-78. 2011
    ..Assessing the relationship between adolescents' high-risk behaviour and family dynamics regarding structure and perception of family functionality...
  14. ncbi request reprint [Health research priorities in Colombia from the researchers' point of view]
    Carlos A Agudelo
    Instituto de Salud Pública, Departamento de Salud Publica, Facultad de Medicina, Universidad Nacional de Colombia, Bogota
    Rev Salud Publica (Bogota) 11:301-9. 2009
    ..Some health research priorities were obtained (by areas and others being overall priorities): chronic diseases, emergent infectious diseases, tuberculosis/leprosy, nosocomial infection and sexually transmitted diseases/HIV/AIDS...